Sala, Eleonora
Nelli, Maria https://orcid.org/0009-0004-5006-0201
Laura, Chiara
Di Lucia, Pietro
Beccaria, Cristian Gabriel https://orcid.org/0000-0001-9682-4415
Bono, Elisa B
Mangione, Marta
Marotta, Davide
Sperto, Valentina https://orcid.org/0009-0009-3160-824X
Grillo, Marta https://orcid.org/0000-0001-9064-2274
Giustini, Leonardo
Tosi, Fabio https://orcid.org/0009-0005-4509-0227
Nie, Jia
Kim, Daehong https://orcid.org/0000-0002-1253-8946
Furiato, Giuliana
Malpighi, Chiara
Consolo, Eleonora
Becher, Burkhard
David, Eyal
Cohen, Merav
Giladi, Amir
Amit, Ido
Bosselut, Remy
Guidotti, Luca G https://orcid.org/0000-0002-0205-2678
Iannacone, Matteo https://orcid.org/0000-0002-9370-2671
Kuka, Mirela https://orcid.org/0000-0001-9418-1559
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (PRIN-20209Y5YFZ)
Ministero dell'Università e della Ricerca (PRIN-P2022YKH9R)
Ministero dell'Università e della Ricerca (PRIN-20224NMLXK)
Ministero dell'Università e della Ricerca (PRIN-P2022Z8HNC)
Ministero dell'Istruzione, dell'Università e della Ricerca (PRIN-2017ZXT5WR)
Ministero dell'Istruzione, dell'Università e della Ricerca (SIR-RBSI14BAO5)
Ministero dell'Istruzione, dell'Università e della Ricerca (PE00000007,INF-ACT)
Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (GR-2021-12372615)
Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (RF-2018-12365801)
EC | European Research Council (Consolidator Grant 725038)
EC | European Research Council (Proof of Concept Grant 957502)
Gilead Sciences (Sponsored Research Agreements)
Asher Biotherapeutics (Sponsored Research Agreements)
Vir Biotechnology (Sponsored Research Agreements)
Italian Association for Cancer Research (19891)
Italian Association for Cancer Research (22737)
Fondazione SAME (Donation)
Fondazione Prossimo Mio (Fellowship)
Article History
Received: 17 September 2024
Revised: 23 February 2025
Accepted: 3 March 2025
First Online: 1 April 2025
Disclosure and competing interests statement
: MI participated in advisory boards/consultantship for Asher Biotherapeutics, GentiBio, Clexio Biosciences, Sybilla Biotech, BlueJay Therapeutics, Bristol Myers Squibb, Aligos Therapeutics and receives funding from Asher Biotherapeutics and VIR Biotechnology. LGG participated in boards, advisory boards and consultantships for Genenta Science, Epsilen Bio, Gilead Sciences, Antios Therapeutics, Aligos Therapeutics, Medicxi, Chroma Medicine and Ananda Immunotherapies. The other authors declare no competing interests.